News
📈 Stocks
ORIC Pharmaceuticals Launches Phase 3 Prostate Cancer Trial With $387M Runway
(just now)
ORIC Pharmaceuticals advances its clinical pipeline with a new Phase 3 prostate cancer trial, balancing a robust cash runway against significant share…